Recipharm AB and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102
Under the terms of the agreement, RecipharmCobra Biologics will continue to advance KAHR-102 for future pre-clinical and clinical testing using RecipharmCobra’s maxXpress service.
Peter Coleman, General Manager at RecipharmCobra Biologics, said: “We are extremely pleased that our development partnership continues with KAHR. Our partnership with KAHR has strengthened over the years due to the strong working relationship between both technical teams and we look forward to its continuation. It is an endorsement of the working relationship we invest in with our customers.”
Dr. Noam Shani, CEO of KAHR Medical, said “It has been a pleasure working with RecipharmCobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of KAHR-102.”
About SCP (Signal Converter Proteins)
SCP molecules represent a paradigm-shift in protein-based drug development because they integrate two functional sides within the same molecule. Unlike conventional biologicals that only have one functional side, the two active sides of SCP drugs allows for multi-functionality. SCP molecules are able to block or induce two cell signals and to convert signals sent from one cell to another.
About RecipharmCobra’s maxXpress service
RecipharmCobra’s maxXpress service combines the expertise and experience of their cell line development team with the powerful UCOE technology and can offer the following advantages over the traditional DHFR–amplification system.
- Enables rapid production of gram quantities of antibodies and recombinant proteins
- Ensures efficient expression, independent of chromosomal integration
- Evaluated for recombinant antibodies, secreted and intracellular proteins
- Eliminates the need to screen 1,000s of clones
- Unique mechanism that prevents gene silencing through effects on chromatin structure
- Generates purified mixed clonal pool material in 10 weeks
KAHR Medical is a portfolio company of Hadasit Bio-Holdings. KAHR develops novel drugs that are based on the SCP (Signal Converter Proteins) platform technology for the treatment of cancer and autoimmune diseases. For more information please visit - www.kahr-medical.com.
About Hadasit Bio-Holdings
Hadasit Bio-Holdings LTD (traded on the Tel-Aviv stock exchange since 2006 under the symbol HDST) is the publicly traded holding company of Hadasit, the technology transfer company of Hadassah Medical Organization. Hadasit Bio-Holdings invests in seven portfolio biotech companies that are based on Hadassah scientific research. For more information please visit - www.hbl.co.il.
About RecipharmCobra Biologics
RecipharmCobra Biologics has a proven track record in the development and manufacture of monoclonal antibodies, recombinant therapeutic proteins, viruses and DNA as well as cell based vaccines and therapies for clinical trials and regulatory approvals. RecipharmCobra Biologics has two GMP approved production facilities, from which a comprehensive service is provided; including cell line development, process and analytical development, GMP manufacture, coordination of formulation and fill/finish activities, and release to clinic.
RecipharmCobra is the specialist biologics division of Recipharm AB. www.recipharmcobrabio.com
Recipharm AB is a leading contract development and manufacturing organisation based in Sweden with 2,000 employees. The company operates 12 development and manufacturing facilities in Sweden, France, the UK, Spain and Germany and is headquartered near Stockholm. We supply the global pharmaceuticals market with hundreds of different products in most dosage forms, including solid dose, granulates, powders, sterile liquids and lyophilisates, semisolids, beta-lactams, hormones, and inhalers.
General Manager, RecipharmCobra Biologics
+44 1782 714 181
Tristan Jervis or Alex Heeley
De Facto Communications
email@example.com or firstname.lastname@example.org
+44 207 861 3019/3043